LOGIN  |  REGISTER
Recursion

Acadia Healthcare Announces Date for Third Quarter 2024 Earnings Release

October 10, 2024 | Last Trade: US$45.06 1.28 2.92

FRANKLIN, Tenn. / Oct 10, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2024 results on Wednesday, October 30, 2024, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, October 31, 2024. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.

About Acadia Healthcare

Acadia is a leading provider of behavioral healthcare services across the United States. As of June 30, 2024, Acadia operated a network of 258 behavioral healthcare facilities with approximately 11,400 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. For more information, please visit AcadiaHealthcare.com.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page